An assessment of the impact of herb-drug combinations used by cancer patients
Open Access
- 18 October 2016
- journal article
- research article
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 16 (1) , 393
Abstract
Herb/Dietary Supplements (HDS) are the most popular Complementary and Alternative Medicine (CAM) modality used by cancer patients and the only type which involves the ingestion of substances which may interfere with the efficacy and safety of conventional medicines. This study aimed to assess the level of use of HDS in cancer patients undergoing treatment in the UK, and their perceptions of their effects, using 127 case histories of patients who were taking HDS. Previous studies have evaluated the risks of interactions between HDS and conventional drugs on the basis on numbers of patient using HDSs, so our study aimed to further this exploration by examining the actual drug combinations taken by individual patients and their potential safety. Three hundred seventy-five cancer patients attending oncology departments and centres of palliative care at the Oxford University Hospitals Trust (OUH), Duchess of Kent House, Sobell House, and Nettlebed Hospice participated in a self-administered questionnaire survey about their HDS use with their prescribed medicines. The classification system of Stockley’s Herbal Medicine’s Interactions was adopted to assess the potential risk of herb-drug interactions for these patients. 127/375 (34 %; 95 % CI 29, 39) consumed HDS, amounting to 101 different products. Most combinations were assessed as ‘no interaction’, 22 combinations were categorised as ‘doubt about outcomes of use’, 6 combinations as ‘Potentially hazardous outcome’, one combination as an interaction with ‘Significant hazard’, and one combination as an interaction of “Life-threatening outcome”. Most patients did not report any adverse events. Most of the patients sampled were not exposed to any significant risk of harm from interactions with conventional medicines, but it is not possible as yet to conclude that risks in general are over-estimated. The incidence of HDS use was also less than anticipated, and significantly less than reported in other areas, illustrating the problems when extrapolating results from one region (the UK), in one setting (NHS oncology) in where patterns of supplement use may be very different to those elsewhere.Keywords
This publication has 34 references indexed in Scilit:
- Valerian: No Evidence for Clinically Relevant InteractionsEvidence-Based Complementary and Alternative Medicine, 2014
- The prevalence of usage of herbal medicines among cancer patients.2013
- Hypericum perforatum : Pharmacokinetic, Mechanism of Action, Tolerability, and Clinical Drug-Drug InteractionsPhytotherapy Research, 2013
- Potential interactions of complementary and alternative medicine with cancer therapy in outpatients with gynecological cancer in a comprehensive cancer centerJournal of Cancer Research and Clinical Oncology, 2012
- Complementary and alternative medicines use by Scottish women with breast cancer. What, why and the potential for drug interactions?European Journal of Clinical Pharmacology, 2011
- The use of herbal preparations as complementary and alternative medicine (CAM) in a sample of patients with cancer in JordanComplementary Therapies in Clinical Practice, 2010
- Quantification of acetogenins in Annona muricata linked to atypical parkinsonism in guadeloupeMovement Disorders, 2005
- Increasing trends in elderly persons' use of nonvitamin, nonmineral dietary supplements and concurrent use of medicationsJournal of the American Dietetic Association, 2005
- Herbal medication: potential for adverse interactions with analgesic drugsJournal of Clinical Pharmacy and Therapeutics, 2002
- Acute Cyanide Toxicity Caused by Apricot Kernel IngestionAnnals of Emergency Medicine, 1998